Abstract
ObjectivesBiological disease-modifying antirheumatic drugs (bDMARDs) require specific storage temperatures, but are frequently stored outside the recommended range of 2–8°C. As incorrect storage may affect therapy effectiveness and consequently lead to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have